Maa: Yhdistynyt kuningaskunta
Kieli: englanti
Lähde: MHRA (Medicines & Healthcare Products Regulatory Agency)
Phenoxymethylpenicillin potassium
Crescent Pharma Ltd
J01CE02
Phenoxymethylpenicillin potassium
250mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010101; GTIN: 5017123057137
Continued, please turn over PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PHENOXYMETHYLPENICILLIN 250mg TABLETS BP (Phenoxymethylpenicillin potassium) Front of leaflet - 148.5mm Back of leaflet - 148.5mm What is in this leaflet 1. What Phenoxymethylpenicillin tablet is and what it is used for 2. What you need to know before you take Phenoxymethylpenicillin tablet 3. How to take Phenoxymethylpenicillin tablet 4. Possible side effects 5. How to store Phenoxymethylpenicillin tablet 6. Contents of the pack and other information 1. WHAT PHENOXYMETHYLPENICILLIN TABLET IS AND WHAT IT IS USED FOR Phenoxymethylpenicillin, is an antibiotic, which belongs to a group of medicines called penicillins, which are used to kill bacteria that cause infections in your body. Each tablet contains 250mg of Phenoxymethylpenicillin potassium as the active ingredient. The strength you are given will be decided by your doctor. Phenoxymethylpenicillin potassium is used to treat infections caused by bacteria that are sensitive to penicillins. These infections include: • Infections of the lungs (such as pneumonia and bronchitis) • Ear and throat infections (such as otitis media and pharyngitis) • Other infections (such as infections of the skin and soft tissue, respiratory tract, scarlet fever and erysipelas) Phenoxymethylpenicillin is also used to prevent infections such as: • Prevention of recurrent attacks of rheumatic fever or chorea (infection of the nervous system) • Prevention of lung infections in patients with no spleen or sickle cell disease • Prevention of pneumococcal infection (e.g. in asplenia) 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PHENOXYMETHYLPENICILLIN TABLET Do not take Phenoxymethylpenicillin tablet: • If you have ever had a bad reaction or allergic to any penicillin or cephalosporin antibiotics, or any of the other ingredients listed in section 6 • If you have ever had a skin rash or swelling of the face or neck or shortness of breath when taking any antibiotic Warnings and precautions Talk to your doctor Lue koko asiakirja
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Phenoxymethylpenicillin 250mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Phenoxymethylpenicillin Potassium (1515 I-U/mg) BP 280.00 mg _ _ Excipient with known effect Each tablet contains 52 mg of lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM White flat tablet with break line on the one side & plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Phenoxymethylpenicillin is indicated in the treatment of mild to moderately severe infections caused by penicillin sensitive organisms. Phenoxymethylpenicillin is indicated for the treatment of the following infections: Streptococcal infections: Pharyngitis, scarlet fever, skin and soft tissue infections (eg. erysipelas). Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Vincent’s gingivitis and pharyngitis, pneumonia, otitis media. Prophylactic use: Prophylaxis with oral penicillin has proved effective in preventing recurrence of rheumatic fever and chorea. Consideration should be given to official guidance on the appropriate use antibacterial agent. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults: 250 – 500 mg every 6 hours depending on the severity of the condition. Prophylactic use: 250 mg twice daily is recommended for long term prophylaxis of rheumatic fever. The Elderly: As for adults. Reduce dosage if renal function is markedly impaired._ _ Paediatric population: Over 12 years: As adult dose. 6 – 12 years: 250 mg 6 hourly 1 – 5 years: 125 mg 6 hourly In children under 5 years of age or those who have difficulty swallowing the tablet, a more appropriate solution form of the medicine is recommended for use. In patients with beta-haemolytic streptococcal infection, it is usual to continue treatment at the full dosage for 10 days, in order to minimise the occurrence of secondary complications such as acute nephritis and rheumatic fever. The treatment of otitis me Lue koko asiakirja